ACTRN12622000775718
Completed
未知
Evaluation of the efficacy and safety of MRI guided focused ultrasound (MRgFUS) for focal hand dystonia
St Vincent's Health Network Sydney0 sites11 target enrollmentMay 31, 2022
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- St Vincent's Health Network Sydney
- Enrollment
- 11
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Patients will be included based on a formal diagnosis of focal hand dystonia (of either musician’s dystonia or writer’s subtype) as made by a consultant neurologist with specialisation in movement disorders. All patients must be at least 18 years of age and be willing to provide written consent to participate in the study. Patients must have tried and failed first line therapies for focal hand dystonia including hand therapy, oral medications and/or botulinum toxin injections.
- •All patients must be ambulant at the time of the procedure.
Exclusion Criteria
- •Patients will be excluded if any of the following criteria are fulfilled
- •History of ischaemic stroke or transient ischaemic event
- •History of stereotactic cerebral surgery
- •Diagnosis of unstable cardiac disease
- •Diagnosis of psychiatric disease
- •Cognitive impairment as indicated by a mini\-mental state examination score of \< 24
- •Coagulopathy or on anticoagulation that cannot be withheld for the intervention
- •Skull density ratio of \<0\.3
- •Absolute contraindication to MRI (eg: non\-MR compatible pacemaker/defibrillator or other non\-MR compatible device in situ).
- •Relative contraindication to MRI (such as severe claustrophobia) will be assessed on a case\-by\-case basis
Outcomes
Primary Outcomes
Not specified
Similar Trials
Unknown
Not Applicable
Investigation of the clinical safety and efficacy of iguratimod in patients with rheumatoid arthritisRheumatoid ArthritisJPRN-jRCT1080222730Toyama Chemical Co., Ltd. (Current FUJIFILM Toyama Chemical Co., Ltd.)2,000
Unknown
Not Applicable
Investigation of the clinical safety and efficacy of iguratimod in patients with rheumatoid arthritisRheumatoid ArthritisJPRN-jRCT1080222005Eisai Co., Ltd.2,000
Not yet recruiting
Not Applicable
Investigation of the clinical safety and efficacy of favipiravir (Avigan tablets) in patients with novel or re-emerging influenza virus infectionsJPRN-jRCT1080223849FUJIFILM Toyama Chemical Co., Ltd. (Former Toyama Chemical Co., Ltd.)
Completed
Phase 2
se of Roselle in Bronchial asthma and MalnutritioHealth Condition 1: J454- Moderate persistent asthmaCTRI/2020/08/027013DXN Manufacturing India Pvt Ltd12
Completed
Phase 2
se of Noni juice in Bronchial asthma and malnutritioHealth Condition 1: J454- Moderate persistent asthmaCTRI/2020/08/027012DXN Manufacturing India Pvt Ltd12